Shin-Etsu Chemical Has Developed an Epoch-making Type of Molding Silicone Rubber That Does Not Require Post Cure
28.9.2020 09:00:00 EEST | Business Wire | Press release
In addition to its already being marketed liquid silicone rubber form, Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo, President, Yasuhiko Saitoh) has now developed a molding silicone rubber that also does not require post cure in its millable form.
Shin-Etsu is the first in the industry to have developed a millable (high consistency) type* of silicone rubber that does not require a post cure. Shin-Etsu succeeded in developing this breakthrough product by making use of the unique technology that Shin-Etsu Chemical has cultivated over a long period of years.
In the existing molding method for millable-type silicone rubber, after the initial press cure of the silicone molding is performed, a post cure is carried out in order to drive off the residues that are left within the molded product as a result of the vulcanization agent used in rubber molding as well as the low-molecular siloxane.
Compared to the existing product, the new silicone rubber molding product that Shin-Etsu has developed greatly reduces the amount of low-molecular siloxane content, and by employing an addition-reaction cure system that does not create by-products at the time of a press cure, the process of post cure becomes unnecessary. Because of this, our new product will contribute to molding-makers’ productivity improvements and energy saving, and at the same time, we are expecting that this new product will respond to such customer requests as preventing the adhesion of foreign substances to the molded products.
Furthermore, this new product is suitable for various molding methods such as extrusion molding, transfer molding, calender molding, press molding and injection molding.
With regard to its liquid-type silicone rubber, already ahead of others in the industry, Shin-Etsu Chemical is marketing its LIMS (Liquid Injection Molding System) materials that do not require post cure, and LIMS is being widely used in various fields, mainly for applications in automobile parts.
In September 2017 Shin-Etsu Chemical opened a silicone rubber molding technical center. This Shin-Etsu Molding Technical Laboratory is located in Higashimatsuyama City, Saitama Prefecture, Japan. At this Laboratory a millable injection-molding machine is installed, and we will be carrying out demonstrations there of molding using this new product. Going forward, at this Laboratory we will strive to meet the current and also future requests that are received from our customers by enhancing the technical services we will be able to offer to them.
Silicone rubber combines many superior characteristics such as excellent heat resistance, cold resistance, weatherability and stable electrical insulation properties, all of which are not found in ordinary organic rubber. For this reason, it is used in a wide range of applications such as in automobiles, electric-electronics equipment, OA equipment, home appliances and products for daily use.
Taking advantage of Shin-Etsu Chemical's superior product quality and technological strengths as well as our system for detailed response to our customers' requests, going forward Shin-Etsu will continue to strive to meet the needs of the diversifying market.
* millable type: It involves the use of a mixer, called a “roll mill,” and it is a general term for rubber materials that are being mixed.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200927005079/en/
Contact information
For inquires about this matter, please contact:
Shin-Etsu Chemical Co., Ltd.
Public Relations Dept.
Tetsuya Koishikawa
Tel: 03-3246-5091, or from outside Japan: 81-3-3246-5091
Fax: 03-3246-5096, or from outside Japan: 81-3-3246-5096
e-mail: sec-pr@shinetsu.jp
www.shinetsu.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 12:11:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechnology executive, bringing over two decades of therapeutic and diagnostic R&D experience within industry to Mosaic Therapeutics, with a track record spanning from IND through to NDA/BLA/MAA approval. Most recently he served at BioXcel Therapeutics as EVP, Head of Product Developme
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 10:00:00 EEST | Press release
The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights - equipping executives with the perspective needed to make confident, high-stakes decisions. “Through our work we increasingly s
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 09:00:00 EEST | Press release
As millions of Europeans2 get ready to enjoy the Easter weekend, new research from Samsung finds Europe’s public spaces have become shared screens: 56% of people say they have accidentally looked at a stranger’s phone, citing public transport as the most likely place to notice someone else’s screen (57%). Nearly one in four Europeans2 (24%) admit to looking at someone else’s phone out of curiosity, exposing a stream of private content from personal photos to bank details. Samsung Electronics surveyed 11,000 Europeans2 to support the launch of the Galaxy S26 Ultra, which introduces a built-in Privacy Display. This new hardware-based technology keeps screen content visible only from the front to protect privacy from side angles, without compromising the viewing experience3. The study further reveals a gap between perceived phone privacy and reality: While 48%* feel their own phone use is private when using it in crowded places, 52%** find it easy to view someone else’s screen in public.
RevolKa Reimagines Antibody Engineering with "RevoAb ® "1.4.2026 07:30:00 EEST | Press release
RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allows researchers worldwide to experience RevolKa’s high-performance antibody design. Key Advantages of RevoAb® Speed: Multiple optimi
Global Beauty Market Grows 10% as AI and E-commerce Reshape Consumer Buying1.4.2026 04:00:00 EEST | Press release
NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its State of Beauty 2026 report, showing the global beauty market grew 10% year-on-year, with E-commerce expanding six times faster than in-store sales. The findings highlight a rapid shift to digital-first, AI-influenced commerce across key global markets. As consumer expectations evolve toward convenience, personalization, and seamless digital experiences, beauty brands are under increasing pressure to adapt. From AI-powered product discovery to social commerce and livestream shopping, the path to purchase is becoming more dynamic—requiring brands to move faster and engage consumers across an increasingly complex ecosystem. Key findings from the State of Beauty 2026 report: Global beauty sales grew 10% year-over-year, driven by strong digital acceleration E-commerce is growing 6x faster than in-store sales, reshaping channel strategies 49% of consumers are willing to pay more for locally made products, ref
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
